Clinical trials: Pseudomonas Aeruginosa Infection
Bacterial Infections, Antibiotic Resistant Infection
Phenotypic Profile and Molecular Mechanism of Resistance in Carbapenemase-producing Enterobacterales and Pseudomonas Aeruginosa Isolates From Brazilian Hospitals: Implications for the Introduction of IMIPENEM-RELEBACTAM
The global dissemination of carbapenem-resistant Enterobacteriaceae (CRE) and Pseudomonas aeruginosa (CRPA) are a significant threat to health care, especially for severely ill patients.
- Trial name
- NCT05285046
- Testing
- No intervention
- Where
- Brazil
- Volunteers
- 250 people
- Sponsor
- D'Or Institute for Research and Education
Ventilator Associated Bacterial Pneumonia, Pseudomonas Aeruginosa Infection
A Double-Blind, Placebo-Controlled Study of Nebulized Bacteriophages in Patients With Ventilator-Associated Pneumonia Due to Pseudomonas Aeruginosa
Ventilator-associated pneumonia (VAP) complicates the hospital course of up to 40% of mechanically ventilated patients and is associated with mortality rates approaching 30%, despite appropriate antibiotic therapy (ATB).
- Trial name
- PYOPHANEB (NCT07804082)
- Testing
- Bacteriophages GMP
- Where
- 16 sites in France
- Volunteers
- 184 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Cystic Fibrosis, Chronic Bronchitis
Standard vs. Biofilm Susceptibility Testing in Cystic Fibrosis (CF)
This was a randomized multi-center clinical trial to compare the microbiological efficacy, clinical efficacy, and safety of using standard versus biofilm susceptibility testing of P.
- Trial name
- NCT00153634
- Testing
- IV amikacin, PO azithromycin, IV ceftazidime
- Where
- 8 sites in United States
- Volunteers
- 75 people
- Sponsor
- Seattle Children's Hospital
Carbapenem-Resistant Enterobacteriaceae Infection, Bloodstream Infection
Seven Versus 14 Days of Antibiotic Therapy for Multidrug-resistant Gram-negative Bacilli Infections
Antimicrobial resistance is a major global problem, particularly in hospital-acquired infections (HAIs). Gram-negative bacilli (GNB), including Enterobacterales, Pseudomonas aeruginosa, and Acinetobacter baumannii, are among the…
- Conditions
- Carbapenem-Resistant Enterobacteriaceae Infection, Bloodstream Infection, Severe Infection, Pseudomonas Aeruginosa
- Trial name
- OPTIMISE (NCT05210387)
- Testing
- Duration of therapy
- Where
- 29 sites in Brazil
- Volunteers
- 107 people
- Sponsor
- Hospital Moinhos de Vento
Patients With Complicated Urinary Tract Infections Caused by P. Aeruginosa, Pseudomonas Aeruginosa
Safety and Efficacy Study of Ftortiazinon in the Treatment of Patients With Complicated Urinary Tract Infections Caused by P. Aeruginosa
This study is planned to evaluate the safety and efficacy of the drug Ftortiazinon in combination with the drug Maxipime® in comparison with placebo in combination with the drug Maxipime® in the treatment of hospitalized adult…
- Conditions
- Patients With Complicated Urinary Tract Infections Caused by P. Aeruginosa, Pseudomonas Aeruginosa, Pseudomonas Infections, Urinary Tract Infections
- Trial name
- NCT03638830
- Testing
- Ftortiazinon (tablets 300 mg) full dose + Maxipim
- Where
- 5 sites in Russia
- Volunteers
- 777 people
- Sponsor
- Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation
Cystic Fibrosis
OPTIMIZing Treatment for Early Pseudomonas Aeruginosa Infection in Cystic Fibrosis
The purpose of this trial is to compare the effects of treatment with tobramycin solution for inhalation (TIS) with and without azithromycin in people with cystic fibrosis (CF) age 6 months to 18 years who have early isolation of…
- Trial name
- OPTIMIZE (NCT02054156)
- Testing
- azithromycin, Tobramycin solution for inhalation
- Where
- 45 sites in United States
- Volunteers
- 221 people
- Sponsor
- Bonnie Ramsey
Cystic Fibrosis
Phase 3 Study of Aztreonam for Inhalation Solution (AZLI) in a Continuous Alternating Therapy Regimen for the Treatment of Chronic Pseudomonas Aeruginosa Infection in Patients With CF
The primary objective of this study is to evaluate the safety and efficacy of a CAT regimen with aztreonam for inhalation solution (AZLI) and tobramycin inhalation solution (TIS) in adult and pediatric subjects with cystic…
- Trial name
- AZLI CAT (NCT01641822)
- Testing
- AZLI, Tobramycin inhalation solution
- Where
- 71 sites in United States
- Volunteers
- 107 people
- Sponsor
- Gilead Sciences
Cystic Fibrosis
Tissue Collection From People With Cystic Fibrosis
This study will examine the relationship between bacterial products in lung infections in cystic fibrosis and disease severity. It will examine plasma and lung tissue from cystic fibrosis patients.
- Trial name
- NCT00015756
- Where
- 2 sites in United States
- Volunteers
- 100 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Severe Infection
CONTinuous Infusion Versus Intermittent Dosing of ceftaZidime/AVIbactam in Critically Ill Patients
Ceftazidime/avibactam (CZA) is an essential treatment option for managing infections caused by multidrug-resistant (MDR) gram-negative (G-) bacteria, including Klebsiella pneumoniae OXA-48 and carbapenem-resistant Pseudomonas…
- Trial name
- ZAVICONT (NCT06811727)
- Testing
- Continuos ceftazidime/avibactam infusion, Intermitent dosing as per SMPC
- Where
- Croatia
- Volunteers
- 140 people
- Sponsor
- Ivan Šitum, MD
Cystic Fibrosis, Infection
Anti-pseudomonas IgY to Prevent Infections in Cystic Fibrosis
Hypothesis: Daily gargling with specific avian antibodies against Pseudomonas aeruginosa will prevent infections with this bacteria in patients with Cystic fibrosis (CF).
- Conditions
- Cystic Fibrosis, Infection, Pseudomonas Aeruginosa
- Trial name
- PseudIgY (NCT00633191)
- Testing
- Anti-pseudomonas IgY gargle
- Where
- Sweden
- Volunteers
- 14 people
- Sponsor
- Immunsystem AB
Cystic Fibrosis
A Study Comparing the Efficacy and Tolerability of Tobrineb®/Actitob®/Bramitob® Versus TOBI®
The objectives of the study are to demonstrate that Tobrineb®/Actitob®/Bramitob® is non-inferior to TOBI® in the primary efficacy variable, forced expiratory volume in one second (FEV1) percent of predicted normal, and to compare…
- Trial name
- CT03 Core (NCT00885365)
- Testing
- tobramycin / Bramitob, tobramycin / TOBI
- Where
- 44 sites in Czechia, France and 6 more
- Volunteers
- 324 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
BRONCHIECTASIS
Atorvastatin in Bronchiectasis in Patients With Pseudomonas Aeruginosa
Statins are a class of drug used to prevent heart attacks and strokes by lowering blood cholesterol levels. They have also been found to have a beneficial "side effect" of lowering the level of inflammation in the body.
- Trial name
- NCT01299194
- Testing
- ATORVASTATIN
- Where
- United Kingdom
- Volunteers
- 32 people
- Sponsor
- University of Edinburgh
Gram-negative Bacteremia
Gram-Negative Bloodstream Infection Oral Antibiotic Therapy Trial
The Gram-negative bloodstream infection Oral Antibiotic Therapy trial (The GOAT Trial) is a multi-center, randomized clinical trial that hypothesizes that early transition to oral antibiotic therapy for the treatment of…
- Trial name
- GOAT (NCT06080698)
- Testing
- Intravenous Antibiotics, Oral Antibiotics
- Where
- 11 sites in United States
- Volunteers
- 1,030 people
- Sponsor
- Johns Hopkins University
P. Aeruginosa, Baumannii
An Open Clinical Trial of the Safety and Efficacy of the Drug Fluorothiazinone, 300 Mg Tablets with the Participation of Adult Patients with Chronic Bacterial Cystitis"
This study is designed to evaluate the safety, clinical efficacy and antibacterial activity of the drug Fluorothiazinone, 300 mg tablets, (Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the…
- Conditions
- P. Aeruginosa, Baumannii, Klebsiella Pneumonia, E.coli Infections
- Trial name
- NCT06815549
- Testing
- Fluorothiazinone, tablets 300 mg, Nitrofurantoin 100 MG
- Volunteers
- 280 people
- Sponsor
- Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation
Bronchiectasis Adult, Pseudomonas Aeruginosa Infection
Tobramycin Inhalation Solution for Pseudomonas Aeruginosa Eradication in Bronchiectasis
People with bronchiectasis are prone to Pseudomonas aeruginosa (PA) infections, which can become chronic and lead to increased death rates and disease severity.
- Trial name
- ERASE (NCT06093191)
- Testing
- Tobramycin Inhalant Product, Ciprofloxacin 750 MG, Natural saline inhalation
- Where
- 60 sites in China
- Volunteers
- 371 people
- Sponsor
- Jin-Fu Xu
Neutrophil Extracellular Traps Formation
Neutrophil Extracellular Traps (NETs) Mediated Killing of Carbapenem-resistant Pseudomonas Aeruginosa.
Aim of the work: To determine the killing ability of neutrophils to ATCC 27853, carbapenem-resistant P. aeruginosa. To compare between the ability of ATCC 27853, carbapenem-resistant P. aeruginosa to induce NETs formation.
- Trial name
- NCT06441708
- Testing
- No intervention
- Volunteers
- 50 people
- Sponsor
- Assiut University
Pseudomonas Aeruginosa, Cystic Fibrosis
Open Label Extension to Bridging Study CTBM100C2303
This was an open-label, single arm (uncontrolled) study in participants suffering from cystic fibrosis, who had completed their study participation in CTBM100C2303 (all visits) and who were proven infected with Pseudomonas…
- Trial name
- NCT00982930
- Testing
- Tobramycin inhalation powder
- Where
- 2 sites in Estonia, Russia
- Volunteers
- 55 people
- Sponsor
- Novartis Pharmaceuticals
Pseudomonas Aeruginosa
Molecular Detection Of Efflux Pump and Virulence Factors Genes in Pseudomonas Aeruginosa
Pseudomonas aeruginosa (PA) is a ubiquitous aerobic, non-fermentative Gram-negative rod that is widely associated with nosocomial pneumonia and can lead to severe illness with poor outcomes, particularly in critically ill people…
- Trial name
- Pseudomonas (NCT05642767)
- Testing
- culture on cetrimide agar, Staining with Gram stain, Antibiotic sensitivity testing
- Where
- Egypt
- Volunteers
- 75 people
- Sponsor
- Sohag University
Bronchiectasis, Microbial Colonization
Role of Pseudomonas Aeruginosa Biofilms in Exacerbations in Patients With Bronchiectasis With and Without Chronic Obstructive Pulmonary Disease
Exacerbations, in particular during chronic Pseudomonas aeruginosa (PA) infection, are very important in the prognosis of patients with non-cystic fibrosis bronchiectasis (BE).
- Conditions
- Bronchiectasis, Microbial Colonization, Pseudomonas Aeruginosa, Biofilm
- Trial name
- NCT04803695
- Testing
- Microbial biofilm diagnose
- Where
- Spain
- Volunteers
- 96 people
- Sponsor
- Hospital Clinic of Barcelona
Cystic Fibrosis
Single Dose Escalation Study of TR02 (Sustained Lipid Inhalation Technology [SLIT™] Amikacin) in Participants With Cystic Fibrosis (CF) Having Chronic Infections of Pseudomonas Aeruginosa
The primary purpose of this study is to evaluate the safety and tolerability of three active doses of nebulized amikacin in a SLIT™ formulation.
- Trial name
- NCT06238856
- Testing
- SLIT™ Amikacin
- Volunteers
- 18 people
- Sponsor
- Insmed Incorporated